% = share price change, close 27 Aug → 25 Sep 2026
First positive Phase 3 for mRNA cancer therapy across nine-trial INTerpath program.
RISKPersonalized manufacturing limits scalability and access.
RISKEarly commercial launch with 350+ patient starts in ten weeks.
RISKPost-bariatric hypoglycemia affects approximately 160,000 US patients.
Three biotech leaders disclosed major Phase 3 trial milestones in the last 30 days. Moderna's mRNA cancer therapy achieved first positive Phase 3 readout; Vera's kidney disease drug showed 76% progression risk reduction; Amylyx's first-in-class hypoglycemia therapy met all endpoints.
-
INTerpath-001 met primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in 1,137 melanoma patients.
RELEASE Merck and Moderna Announce Phase 3 INTerpath-001 Trial Success Merck www.merck.com -
TRUTAKNA achieved mean eGFR change of -0.1 versus -5.7 for placebo (p<0.0001) and 76% risk reduction in composite kidney disease progression.
FILING ORIGIN 3 Final Efficacy Analysis Results SEC EDGAR www.sec.gov -
LUCIDITY met primary endpoint with 55% reduction in composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003).
RELEASE Amylyx Announces Positive Phase 3 LUCIDITY Results for Avexitide Amylyx www.amylyx.com
Agent-generated research. May contain errors or omissions. Informational only — not investment advice, not a recommendation to buy or sell any security. Quotes via Yahoo Finance (unaffiliated).
Research the three biotech names with the highest growth potential, as evidenced by disclosed trial milestones, regulatory filings, and manufacturing capacity from the last 30 days. Order the three by growth potential, highest first — the largest and best-evidenced growth the disclosures support at the top — not by recent price momentum. This is growth-potential research: for each name give the growth timeline the company itself disclosed or guided to, and one disclosed fact that cuts against the thesis. Report observations only — no entry or exit points, no price targets, no timing language. Offer no clinical opinion.
- Search trial registries, regulatory filings, and manufacturing disclosures from the last 30 days
- Rank three names by growth potential, highest and best-evidenced first — not price momentum
- For each, record the growth timeline the company itself disclosed
- For each, record one disclosed fact that cuts against the thesis
- Re-open every cited document and confirm it says what the note claims
- Drop any source that cannot be opened or does not support its sentence
- Emit ranked-list JSON within the schema caps
Adds this workflow to your account. Nothing is scheduled until you say so.